ESMO 2021 | Zanidatamab + chemo as 1L therapy in HER2-expressing GEA

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents an update on a Phase II study evaluating zanidatamb and chemotherapy in the first-line (1L) treatment of patients with HER2-expressing gastroesophageal adenocarcinoma (GEA). In this ongoing study, zanidatamab with standard 1L chemotherapy shows an encouraging confirmed objective response rate and response durability in patients with HER2+ gastroesophageal adenocarcinoma with a manageable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.